There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry. But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.
Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.
At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.
Changes to the accounting standards that affect matters like revenue recognition, the definition of a business, and leases could significantly affect the accounting for certain transactions in the life sciences industry.
Biopharma startups are enjoying a window of opportunity for successful IPOs that opened in mid-2017. CEOs share their experiences of going public, what is fueling IPOs, and tips for others thinking about making this important next step.
Many private biotech companies have either initiated the process of going public or are at least contemplating it. But they should be aware of very significant pitfalls that lie in wait, regardless of how they approach the offering.
When the economy crashed a few years ago, crowdfunding offered startups a possible lifeline. But it arrived too late to be much use. Now that money is flooding back into biotech, companies needn’t clutter cap sheets with scores of non-accredited investors, so equity crowdfunding is nearly a nonstarter.
According to Noubar Afeyan, founder and CEO of Flagship Pioneering, his company shouldn’t be pigeonholed as a VC firm. ““From day one, our intent was to innovate and create new companies.”
2018 will be a good year for IPOs and for financing. Rounds are larger and non-traditional investors are turning to life sciences.
Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.